Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 214

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Open access
Ye, Byong Duk, Pesegova, Marina, Alexeeva, Olga, Osipenko, Marina, Lahat, Adi, Dorofeyev, Andriy, Fishman, Sigal, Levchenko, Olena, Cheon, Jae Hee, Scribano, Maria Lia, Mateescu, Radu-Bogdan, Lee, Kang-Moon, Eun, Chang Soo, Lee, Sang Joon, Lee, Sung Young, Kim, HoUng, Schreiber, Stefan, Fowler, Heather, Cheung, Raymond, Kim, Young-Ho · 2019 · The Lancet

Abstract

BACKGROUND The infliximab biosimilar CT-P13 was approved for use in Crohn's disease after clinical comparison with originator infliximab in ankylosing spondylitis and rheumatoid arthritis; however, concerns about such indication extrapolation have been expressed. This study investigated whether CT-P13 is non-inferior to infliximab in patients with Crohn's disease who were naive to biological therapy. METHODS In this randomised, multicentre, double-blind, phase 3 non-inferiority study, we enrolled patients with active Crohn's disease who had not responded to, or were intolerant to, non-biological treatments. Patients were randomly assigned (1:1:1:1) to receive CT-P13 then CT-P13, CT-P13 then infliximab, infliximab then infliximab, or infliximab then CT-P13, with switching occurring at week 30. Patients received 5 mg/kg CT-P13 or infliximab at weeks 0, 2, 6, and then every 8 weeks up to week 54. The primary endpoint was the proportion of patients with a decrease of 70 points or more in Crohn's Disease Activity Index (CDAI) from baseline to week 6. A non-inferiority margin of -20% was set (CT-P13 was non-inferior to infliximab if the lower limit of the two-sided 95% CI for the treatment difference was greater than -20). This trial is registered with ClinicalTrials.gov, number NCT02096861, and is completed. FINDINGS Between Aug 20, 2014, and Feb 15, 2017, 308 patients were assessed for eligibility, and 220 patients were enrolled: 111 were randomly assigned to initiate CT-P13 (56 to the CT-P13-CT-P13 group and 55 to the CT-P13-infliximab group) and 109 to initiate infliximab (54 to the infliximab-infliximab group and 55 to the infliximab-CT-P13 group). CDAI-70 response rates at week 6 were similar for CT-P13 (77 [69·4%, 95% CI 59·9 to 77·8] of 111) and infliximab (81 [74·3%, 95% CI 65·1 to 82·2] of 109; difference -4·9% [95% CI -16·9 to 7·3]), thereby establishing non-inferiority. Over the total study period, 147 (67%) patients experienced at least one treatment-emergent adverse event (36 [64%] in the CT-P13-CT-P13 group, 34 [62%] in the CT-P13-infliximab group, 37 [69%] in the infliximab-infliximab group, and 40 [73%] in the infliximab-CT-P13 group). INTERPRETATION This study showed non-inferiority of CT-P13 to infliximab in patients with active Crohn's disease. Biosimilar CT-P13 could be a new option for the treatment of active Crohn's disease. FUNDING Celltrion, Pfizer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)32196-2

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 214

Metadata

Authors
Ye, B. D., Pesegova, M., Alexeeva, O., Osipenko, M., Lahat, A., Dorofeyev, A., Fishman, S., Levchenko, O., Cheon, J. H., Scribano, M. L., Mateescu, R.-B., Lee, K.-M., Eun, C. S., Lee, S. J., Lee, S. Y., Kim, H., Schreiber, S., Fowler, H., Cheung, R., & Kim, Y.-H.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-04
Volume
393
Issue
10182
Pages
1699-1707
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2923675504
Cited by
214
References
1
FWCI
18.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. https://app.cochat.ai/papers/10.1016/s0140-6736(18)32196-2
The paper
Ye, B. D., Pesegova, M., Alexeeva, O., Osipenko, M., Lahat, A., Dorofeyev, A., Fishman, S., Levchenko, O., Cheon, J. H., Scribano, M. L., Mateescu, R.-B., Lee, K.-M., Eun, C. S., Lee, S. J., Lee, S. Y., Kim, H., Schreiber, S., Fowler, H., Cheung, R., & Kim, Y.-H. (2019). Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. The Lancet. https://doi.org/10.1016/s0140-6736(18)32196-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.